Showing results (41-50 of 51) with videos related to
Sort By:
Pageof 6
Cancer Discovery|April 4, 2018
E-Cadherin/ROS1 Inhibitor Synthetic Lethality in Breast CancerIlirjana Bajrami, Rebecca Marlow, Marieke van de Ven, et al.Biorxiv : the Preprint Server for Biology|April 2, 2024
CDK12 Loss Promotes Prostate Cancer Development While Exposing Vulnerabilities to Paralog-Based Synthetic LethalityJean Ching-Yi Tien, Yu Chang, Yuping Zhang, et al.Nature Communications|March 12, 2026
Tumour specific HORMAD1 expression perturbs mitotic arrest and drives sensitivity to mitotic kinase inhibitorsCallum Walker, Gabriel Kollarovic, Daniel Weekes, et al.Cell Reports. Medicine|October 5, 2024
CDK12 loss drives prostate cancer progression, transcription-replication conflicts, and synthetic lethality with paralog CDK13Jean Ching-Yi Tien, Jie Luo, Yu Chang, et al.NPJ Precision Oncology|July 11, 2026
Comprehensive clinical cancer analysis of homologous recombination deficiency biomarkers in an academic molecular profiling programHeura Domènech, Sara Simonetti, Paula Romero-Lozano, et al.Cancer Discovery|June 14, 2020
Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non-BRCA1/2-Mutant CancersTimothy A Yap, Rebecca Kristeleit, Vasiliki Michalarea, et al.Molecular Cancer Therapeutics|July 15, 2026
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor CombinationsAnh Minh Tran Huynh, Jonathan T Lei, Rachel Brough, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 3, 2022
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor ResistanceVioleta Serra, Anderson T Wang, Marta Castroviejo-Bermejo, et al.Cell Reports|May 14, 2020
HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic CancerHolly Brunton, Giuseppina Caligiuri, Richard Cunningham, et al.Nature Communications|June 18, 2021
Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistanceDiana Zatreanu, Helen M R Robinson, Omar Alkhatib, et al.Pageof 6